Ferraro Gino B, Ali Ahmed, Luengo Alba, Kodack David P, Deik Amy, Abbott Keene L, Bezwada Divya, Blanc Landry, Prideaux Brendan, Jin Xin, Posada Jessica M, Chen Jiang, Chin Christopher R, Amoozgar Zohreh, Ferreira Raphael, Chen Ivy X, Naxerova Kamila, Ng Christopher, Westermark Anna M, Duquette Mark, Roberge Sylvie, Lindeman Neal I, Lyssiotis Costas A, Nielsen Jens, Housman David E, Duda Dan G, Brachtel Elena, Golub Todd R, Cantley Lewis C, Asara John M, Davidson Shawn M, Fukumura Dai, Dartois Véronique A, Clish Clary B, Jain Rakesh K, Vander Heiden Matthew G
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Nat Cancer. 2021 Apr;2(4):414-428. doi: 10.1038/s43018-021-00183-y. Epub 2021 Apr 1.
Brain metastases are refractory to therapies that control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the brain microenvironment contributes to this therapy resistance. Nutrient availability can vary across tissues, therefore metabolic adaptations required for brain metastatic breast cancer growth may introduce liabilities that can be exploited for therapy. Here, we assessed how metabolism differs between breast tumors in brain versus extracranial sites and found that fatty acid synthesis is elevated in breast tumors growing in brain. We determine that this phenotype is an adaptation to decreased lipid availability in brain relative to other tissues, resulting in a site-specific dependency on fatty acid synthesis for breast tumors growing at this site. Genetic or pharmacological inhibition of fatty acid synthase (FASN) reduces HER2+ breast tumor growth in the brain, demonstrating that differences in nutrient availability across metastatic sites can result in targetable metabolic dependencies.
脑转移对控制人表皮生长因子受体2(HER2+)乳腺癌患者全身疾病的疗法具有抗性,并且脑微环境促成了这种治疗抗性。不同组织的营养物质供应情况可能不同,因此脑转移性乳腺癌生长所需的代谢适应可能会带来可用于治疗的弱点。在这里,我们评估了脑内与颅外部位的乳腺肿瘤之间的代谢差异,发现脑内生长的乳腺肿瘤中脂肪酸合成增加。我们确定这种表型是对脑内相对于其他组织脂质供应减少的一种适应,导致在该部位生长的乳腺肿瘤对脂肪酸合成产生位点特异性依赖。脂肪酸合酶(FASN)的基因或药理学抑制可减少脑内HER2+乳腺肿瘤的生长,表明转移部位营养物质供应的差异可导致可靶向的代谢依赖性。